Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human Phase 1 single ascending dose study assessing ART2612

Next Previous
X
Search
Trial Profile

First-in-human Phase 1 single ascending dose study assessing ART2612

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ART 2612 (Primary)
  • Indications Chemotherapy-induced damage; Peripheral neuropathies
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 03 Mar 2025 According to Artelo Biosciences media release, enrollment in Phase 1 study of ART26.12, has progressed rapidly and is expected to conclude in the second quarter of this year.
    • 13 Jan 2025 According to Artelo Biosciences media release, results from this Phase 1 single ascending dose study are intended to determine the most suitable doses of ART26.12. to utilize in a multiple ascending dose phase 1 planned study.
    • 13 Jan 2025 Status changed to recruiting, according to Artelo Biosciences media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top